AI
NBIX icon

AdvisorShares Investments’s Neurocrine Biosciences NBIX Stock Holding History

AdvisorShares Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95M Buy
11,553
+4,383
+61% +$650K 0.24% 51
2026
Q1 		$945K Buy
7,170
+1,269
+22% +$168K 0.17% 79
2025
Q4 		$837K Buy
5,901
+929
+19% +$135K 0.14% 90
2025
Q3 		$698K Buy
4,972
+1,306
+36% +$177K 0.11% 94
2025
Q2 		$461K Buy
3,666
+100
+3% +$11.5K 0.08% 170
2025
Q1 		$382K Buy
3,566
+1,536
+76% +$195K 0.07% 189
2024
Q4 		$277K Buy
+2,030
New +$251K 0.05% 204

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AdvisorShares Investments's NBIX Position: Q2 2026 in Review

AdvisorShares Investments increased its Neurocrine Biosciences (NBIX) stake by 61% in Q2 2026, buying an estimated $650K and bringing the position to 11,553 shares worth $1.95M. The position accounts for 0.24% of the portfolio, ranked #51.

AdvisorShares Investments first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • AdvisorShares Investments held 11,553 shares of Neurocrine Biosciences worth $1.95M as of Q2 2026.
  • AdvisorShares Investments bought 4,383 Neurocrine Biosciences shares in Q2 2026, an estimated $650K.
  • Neurocrine Biosciences made up 0.24% of AdvisorShares Investments's portfolio in Q2 2026, its #51 holding.
  • AdvisorShares Investments first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on AdvisorShares Investments's 13F filing for Q2 2026, filed 11 Aug 2026.